

# Jonathan Strosberg

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1631425/publications.pdf>

Version: 2024-02-01

84  
papers

7,939  
citations

101496

36  
h-index

62565

80  
g-index

86  
all docs

86  
docs citations

86  
times ranked

6057  
citing authors

| #  | ARTICLE   | IF    | CITATIONS |
|----|---|-------|-----------|
| 1  | Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors. <i>New England Journal of Medicine</i> , 2017, 376, 125-135.  | 13.9  | 2,206     |
| 2  | Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. <i>Lancet</i> , The, 2016, 387, 968-977.  | 6.3   | 962       |
| 3  | First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. <i>Cancer</i> , 2011, 117, 268-275.   | 2.0   | 647       |
| 4  | Gastroenteropancreatic Neuroendocrine Tumors. <i>Ca-A Cancer Journal for Clinicians</i> , 2018, 68, 471-487.  | 157.7 | 378       |
| 5  | Health-Related Quality of Life in Patients With Progressive Midgut Neuroendocrine Tumors Treated With <sup>177</sup> Lu-Dotatate in the Phase III NETTER-1 Trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 2578-2584.  | 0.8   | 276       |
| 6  | Consensus on biomarkers for neuroendocrine tumour disease. <i>Lancet Oncology</i> , The, 2015, 16, e435-e446.   | 5.1   | 217       |
| 7  | Improved Outcome With Cytoreduction Versus Embolization for Symptomatic Hepatic Metastases of Carcinoid and Neuroendocrine Tumors. <i>Annals of Surgical Oncology</i> , 2006, 13, 572-581.  | 0.7   | 211       |
| 8  | <sup>177</sup> Lu-Dotatate plus long-acting octreotide versus high-dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 1752-1763. | 5.1   | 195       |
| 9  | Survival and Prognostic Factor Analysis of 146 Metastatic Neuroendocrine Tumors of the Mid-Gut. <i>Neuroendocrinology</i> , 2009, 89, 471-476.  | 1.2   | 149       |
| 10 | Relapse-Free Survival in Patients With Nonmetastatic, Surgically Resected Pancreatic Neuroendocrine Tumors. <i>Annals of Surgery</i> , 2012, 256, 321-325.  | 2.1   | 134       |
| 11 | Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Neuroendocrine Tumors: Results From the Phase II KEYNOTE-158 Study. <i>Clinical Cancer Research</i> , 2020, 26, 2124-2130.  | 3.2   | 132       |
| 12 | Correlation between grade and prognosis in metastatic gastroenteropancreatic neuroendocrine tumors. <i>Human Pathology</i> , 2009, 40, 1262-1268.   | 1.1   | 126       |
| 13 | Consensus on molecular imaging and theranostics in neuroendocrine neoplasms. <i>European Journal of Cancer</i> , 2021, 146, 56-73.  | 1.3   | 120       |
| 14 | Incidental Detection of Pancreatic Neuroendocrine Tumors: An Analysis of Incidence and Outcomes. <i>Annals of Surgical Oncology</i> , 2012, 19, 2932-2936.  | 0.7   | 114       |
| 15 | Radionuclide Therapy for Neuroendocrine Tumors. <i>Current Oncology Reports</i> , 2017, 19, 9.  | 1.8   | 113       |
| 16 | Multicenter Phase II Trial of Temsirolimus and Bevacizumab in Pancreatic Neuroendocrine Tumors. <i>Journal of Clinical Oncology</i> , 2015, 33, 1551-1556.  | 0.8   | 110       |
| 17 | Antiproliferative effect of somatostatin analogs in gastroenteropancreatic neuroendocrine tumors. <i>World Journal of Gastroenterology</i> , 2010, 16, 2963.  | 1.4   | 104       |
| 18 | A Delphic consensus assessment: imaging and biomarkers in gastroenteropancreatic neuroendocrine tumor disease management. <i>Endocrine Connections</i> , 2016, 5, 174-187.  | 0.8   | 83        |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 19 | Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with 177Lu-Dotatate: an analysis of the NETTER-1 study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 2372-2382. | 3.3 | 79        |
| 20 | Phase II clinical trial of pasireotide long-acting repeatable in patients with metastatic neuroendocrine tumors. <i>Endocrine-Related Cancer</i> , 2015, 22, 1-9.  | 1.6 | 76        |
| 21 | Neuroendocrine tumours of the small intestine. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2012, 26, 755-773.   | 1.0 | 75        |
| 22 | Everolimus in advanced, progressive, well-differentiated, non-functional neuroendocrine tumors: <sup>RADIANT</sup> lung subgroup analysis. <i>Cancer Science</i> , 2018, 109, 174-181.   | 1.7 | 72        |
| 23 | A Review of Systemic and Liver-Directed Therapies for Metastatic Neuroendocrine Tumors of the Gastroenteropancreatic Tract. <i>Cancer Control</i> , 2011, 18, 127-137.   | 0.7 | 71        |
| 24 | <sup>177</sup>Lu-DOTATATE for the treatment of gastroenteropancreatic neuroendocrine tumors. <i>Expert Review of Gastroenterology and Hepatology</i> , 2019, 13, 1023-1031.  | 1.4 | 60        |
| 25 | Metastatic carcinoid tumor to the ovary: A clinicopathologic analysis of seventeen cases. <i>Gynecologic Oncology</i> , 2007, 106, 65-68.  | 0.6 | 58        |
| 26 | Survival and Prognostic Factor Analysis in Patients With Metastatic Pancreatic Endocrine Carcinomas. <i>Pancreas</i> , 2009, 38, 255-258.  | 0.5 | 54        |
| 27 | A phase II clinical trial of sunitinib following hepatic transarterial embolization for metastatic neuroendocrine tumors. <i>Annals of Oncology</i> , 2012, 23, 2335-2341.   | 0.6 | 53        |
| 28 | Treatment Strategies for Metastatic Neuroendocrine Tumors of the Gastrointestinal Tract. <i>Current Treatment Options in Oncology</i> , 2017, 18, 14.  | 1.3 | 52        |
| 29 | Spartalizumab in metastatic, well/poorly differentiated neuroendocrine neoplasms. <i>Endocrine-Related Cancer</i> , 2021, 28, 161-172.   | 1.6 | 52        |
| 30 | Molecular profiling of neuroendocrine tumours to predict response and toxicity to peptide receptor radionuclide therapy. <i>Lancet Oncology</i> , The, 2020, 21, e431-e443.  | 5.1 | 51        |
| 31 | A phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG S1609; High-grade neuroendocrine neoplasm cohort. <i>Cancer</i> , 2021, 127, 3194-3201.  | 2.0 | 48        |
| 32 | An update on gastroenteropancreatic neuroendocrine tumors. <i>Oncology</i> , 2014, 28, 749-56, 758.  | 0.4 | 45        |
| 33 | Peptide receptor radiotherapy re-treatment in patients with progressive neuroendocrine tumors: A systematic review and meta-analysis. <i>Cancer Treatment Reviews</i> , 2021, 93, 102141.  | 3.4 | 43        |
| 34 | The Expanding Role of Somatostatin Analogs in Gastroenteropancreatic and Lung Neuroendocrine Tumors. <i>Drugs</i> , 2015, 75, 847-858.   | 4.9 | 42        |
| 35 | Capecitabine and Temozolomide in Advanced Lung Neuroendocrine Neoplasms. <i>Oncologist</i> , 2020, 25, e48-e52.  | 1.9 | 42        |
| 36 | A phase II study of axitinib in advanced neuroendocrine tumors. <i>Endocrine-Related Cancer</i> , 2016, 23, 411-418.   | 1.6 | 38        |

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 37 | Update on the Management of Unusual Neuroendocrine Tumors: Pheochromocytoma and Paraganglioma, Medullary Thyroid Cancer and Adrenocortical Carcinoma. <i>Seminars in Oncology</i> , 2013, 40, 120-133.   | 0.8  | 37        |
| 38 | <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors. <i>New England Journal of Medicine</i> , 2017, 376, 1390-1392.  | 13.9 | 35        |
| 39 | A multi-institutional, phase II open-label study of ganitumab (AMG 479) in advanced carcinoid and pancreatic neuroendocrine tumors. <i>Endocrine-Related Cancer</i> , 2013, 20, 383-390.   | 1.6  | 32        |
| 40 | Outcomes of Therasphere Radioembolization for Colorectal Metastases. <i>Clinical Colorectal Cancer</i> , 2015, 14, 146-153.  | 1.0  | 32        |
| 41 | Risk of Bowel Obstruction in Patients with Mesenteric or Peritoneal Disease Receiving Peptide Receptor Radionuclide Therapy. <i>Journal of Nuclear Medicine</i> , 2021, 62, 69-72.   | 2.8  | 30        |
| 42 | A phase I/IIb study of regorafenib and nivolumab in mismatch repair proficient advanced refractory colorectal cancer. <i>European Journal of Cancer</i> , 2022, 169, 93-102.   | 1.3  | 30        |
| 43 | Novel immunotherapy strategies for treatment of neuroendocrine neoplasms. <i>Translational Gastroenterology and Hepatology</i> , 2020, 5, 54-54.   | 1.5  | 29        |
| 44 | Will clinical heterogeneity of neuroendocrine tumors impact their management in the future? Lessons from recent trials. <i>Current Opinion in Oncology</i> , 2016, 28, 359-366.  | 1.1  | 28        |
| 45 | TheraSphere Yttrium-90 Glass Microspheres Combined With Chemotherapy Versus Chemotherapy Alone in Second-Line Treatment of Patients With Metastatic Colorectal Carcinoma of the Liver: Protocol for the EPOCH Phase 3 Randomized Clinical Trial. <i>JMIR Research Protocols</i> , 2019, 8, e11545. | 0.5  | 27        |
| 46 | RUNX1T1. <i>Pancreas</i> , 2011, 40, 627-633.  | 0.5  | 26        |
| 47 | DAXX mutations as potential genomic markers of malignant evolution in small nonfunctioning pancreatic neuroendocrine tumors. <i>Scientific Reports</i> , 2019, 9, 18614.   | 1.6  | 26        |
| 48 | Effective Treatment of Locally Advanced Endocrine Tumors of the Pancreas with Chemoradiotherapy. <i>Neuroendocrinology</i> , 2007, 85, 216-220.  | 1.2  | 24        |
| 49 | Emerging Treatment Options for Gastroenteropancreatic Neuroendocrine Tumors. <i>Journal of Clinical Medicine</i> , 2020, 9, 3655.  | 1.0  | 23        |
| 50 | Treatment of Metastatic Neuroendocrine Tumors of the Thymus with Capecitabine and Temozolomide: A Case Series. <i>Neuroendocrinology</i> , 2013, 97, 318-321.  | 1.2  | 20        |
| 51 | A phase I/2 trial of ibrutinib in combination with pembrolizumab in patients with mismatch repair proficient metastatic colorectal cancer. <i>British Journal of Cancer</i> , 2021, 124, 1803-1808.  | 2.9  | 20        |
| 52 | TELEPRO: Patient-Reported Carcinoid Syndrome Symptom Improvement Following Initiation of Telotristat Ethyl in the Real World. <i>Oncologist</i> , 2019, 24, 1446-1452.   | 1.9  | 19        |
| 53 | Medical Management of Gastroenteropancreatic Neuroendocrine Tumors: Current Strategies and Future Advances. <i>Journal of Nuclear Medicine</i> , 2019, 60, 721-727.  | 2.8  | 15        |
| 54 | A Phase II Study of Ibrutinib in Advanced Neuroendocrine Neoplasms. <i>Neuroendocrinology</i> , 2020, 110, 377-383.  | 1.2  | 15        |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 55 | Somatostatin Analogs Improve Respiratory Symptoms in Patients With Diffuse Idiopathic Neuroendocrine Cell Hyperplasia. <i>Chest</i> , 2020, 158, 401-405.  | 0.4 | 15        |
| 56 | Efficacy of FOLFOX in Patients with Aggressive Pancreatic Neuroendocrine Tumors After Prior Capecitabine/Temozolomide. <i>Oncologist</i> , 2021, 26, 115-119.  | 1.9 | 15        |
| 57 | Chemotherapy in Neuroendocrine Tumors. <i>Cancers</i> , 2021, 13, 4872.  | 1.7 | 13        |
| 58 | Surgical Treatment of an Isolated Metastatic Myocardial Neuroendocrine Tumor. <i>Annals of Thoracic Surgery</i> , 2016, 101, 747-749.  | 0.7 | 11        |
| 59 | Evolving Treatment Strategies for Management of Carcinoid Tumors. <i>Current Treatment Options in Oncology</i> , 2013, 14, 374-388.  | 1.3 | 10        |
| 60 | Biology and Systemic Treatment of Advanced Gastroenteropancreatic Neuroendocrine Tumors. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2018, 38, 292-299. | 1.8 | 9         |
| 61 | Somatostatin receptor radionuclide therapy in neuroendocrine tumors. <i>Endocrine-Related Cancer</i> , 2021, 28, R81-R93.  | 1.6 | 9         |
| 62 | Perioperative Carcinoid Crisis: A Systematic Review and Meta-Analysis. <i>Cancers</i> , 2022, 14, 2966.  | 1.7 | 9         |
| 63 | Efficacy of Capecitabine and Temozolomide in Small Bowel (Midgut) Neuroendocrine Tumors. <i>Current Oncology</i> , 2022, 29, 510-515.  | 0.9 | 8         |
| 64 | Peptide Receptor Radiotherapy Comes of Age. <i>Endocrinology and Metabolism Clinics of North America</i> , 2018, 47, 615-625.  | 1.2 | 7         |
| 65 | Partial Splenic Artery Embolization in 35 Cancer Patients: Results of a Single Institution Retrospective Study. <i>Journal of Vascular and Interventional Radiology</i> , 2020, 31, 584-591.                                     | 0.2 | 7         |
| 66 | Molecular imaging and radionuclide therapy of neuroendocrine tumors. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2020, 27, 16-21.  | 1.2 | 7         |
| 67 | Moving Beyond the Momentum: Innovative Approaches to Clinical Trial Implementation. <i>JCO Oncology Practice</i> , 2021, 17, 607-614.  | 1.4 | 7         |
| 68 | Peptide Receptor Radionuclide Therapy During the COVID-19 Pandemic: Are There Any Concerns?. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1094-1095.   | 2.8 | 6         |
| 69 | Sensitivity and Specificity of the NETest: A Validation Study. <i>Neuroendocrinology</i> , 2021, 111, 580-585.   | 1.2 | 6         |
| 70 | Markers of Systemic Inflammation in Neuroendocrine Tumors. <i>Pancreas</i> , 2021, 50, 130-137.  | 0.5 | 6         |
| 71 | Health-Related Quality of Life (HRQoL) in Neuroendocrine Tumors: A Systematic Review. <i>Cancers</i> , 2022, 14, 1428.   | 1.7 | 6         |
| 72 | External beam irradiation of myocardial carcinoid metastases: a case report. <i>Journal of Medical Case Reports</i> , 2007, 1, 95.   | 0.4 | 5         |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 73 | Comparison of Nausea and Vomiting Associated With Amino Acid Formulations Coinfused With Peptide Receptor Radionuclide Therapy. <i>Pancreas</i> , 2021, 50, 513-515.                  | 0.5 | 5         |
| 74 | Radioembolization Versus Bland or Chemoembolization for Liver-Dominant Neuroendocrine Tumors: Is It an Either/Or Question?. <i>Journal of Nuclear Medicine</i> , 2021, 62, 1669-1671. | 2.8 | 5         |
| 75 | Pancreatic NETs: where do we stand now?. <i>Cancer and Metastasis Reviews</i> , 2014, 33, 361-366.  | 2.7 | 4         |
| 76 | Desmoplastic mesenteric lesions do not respond radiographically to peptide receptor radionuclide therapy. <i>Journal of Neuroendocrinology</i> , 2021, 33, e12936.                    | 1.2 | 3         |
| 77 | An Update on the Management of Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia (DIPNECH). <i>Current Treatment Options in Oncology</i> , 2021, 22, 28.                   | 1.3 | 3         |
| 78 | Clinical Benefits of Telotristat Ethyl in Patients With Neuroendocrine Tumors and Low Bowel Movement Frequency. <i>Pancreas</i> , 2020, 49, 408-412.                                  | 0.5 | 2         |
| 79 | What is the role of checkpoint inhibitors in neuroendocrine neoplasms?. <i>Oncotarget</i> , 2020, 11, 3751-3752.  | 0.8 | 2         |
| 80 | Reply: Bowel Obstruction as a Complication of Peptide Receptor Radionuclide Therapy. <i>Journal of Nuclear Medicine</i> , 2021, 62, 1321-1321.  | 2.8 | 1         |
| 81 | Congenital Anomaly Detected During Work-up of Cystic Pancreatic Lesion. <i>Gastroenterology</i> , 2015, 149, 33-34.   | 0.6 | 0         |
| 82 | Management of NETs in the Precision Medicine Era. , 2019, , 575-589.  |     | 0         |
| 83 | Radioembolization for Metastatic Neuroendocrine Tumors. <i>Digestive Disease Interventions</i> , 0, 05, .   | 0.3 | 0         |
| 84 | Multiple Tumors in a Young Patient. <i>Gastroenterology</i> , 2022, 163, e13-e15.   | 0.6 | 0         |